SCM
GYRE icon

Sterling Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Sterling Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06K Buy
161
+102
+173% +$695 ﹤0.01% 3118
2026
Q1 		$411 Hold
59
– – ﹤0.01% 3168
2025
Q4 		$417 Buy
59
+37
+168% +$286 ﹤0.01% 3203
2025
Q3 		$164 Sell
22
-11
-33% -$84 ﹤0.01% 3222
2025
Q2 		$243 Sell
33
-73
-69% -$637 ﹤0.01% 3225
2025
Q1 		$818 Sell
106
-110
-51% -$1.21K ﹤0.01% 2877
2024
Q4 		$2.61K Buy
216
+195
+929% +$2.5K ﹤0.01% 2703
2024
Q3 		$263 Buy
+21
New +$271 ﹤0.01% 3063

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Sterling Capital Management's GYRE Position: Q2 2026 in Review

Sterling Capital Management increased its Gyre Therapeutics (GYRE) stake by 173% in Q2 2026, buying an estimated $695 and bringing the position to 161 shares worth $1.06K. The position accounts for ﹤0.01% of the portfolio, ranked #3118.

Sterling Capital Management first reported a position in GYRE in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.61K in Q4 2024. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • Sterling Capital Management held 161 shares of Gyre Therapeutics worth $1.06K as of Q2 2026.
  • Sterling Capital Management bought 102 Gyre Therapeutics shares in Q2 2026, an estimated $695.
  • Gyre Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3118 holding.
  • Sterling Capital Management first reported a position in Gyre Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Gyre Therapeutics position peaked at $2.61K in Q4 2024.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.